Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALDA Products Now Available at Marketplace IGA
VANCOUVER, BRITISH COLUMBIA, Nov 25, 2009 (MARKETWIRE via COMTEX News Network) --
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCBB: APCSF) ("the Company" or "ALDA") announces that T36(R) Antiseptic Hand Sanitizer is now available through Marketplace IGA which has 42 stores located throughout British Columbia. Dr. Terrance Owen, President & CEO, states, "Selling through Marketplace IGA is another important step for ALDA. We are pleased that our customers will be able to purchase our products in the communities served by Marketplace IGA now that the H1N1 pandemic is in full swing."
About Marketplace IGA (www.marketplaceiga.com)
Marketplace IGA serves 30 communities in British Columbia by searching for the best local growers, premium ingredients and fresh picks from land and sea, bringing its customers quality choices of meats, seafood, produce, deli products, baked goods, fresh cut flowers and personal care products, the category in which T36(R) Antiseptic Hand Sanitizer will be found. With a long history in BC, Marketplace IGA has become a trusted source of quality products across the entire province.
About ALDA Pharmaceuticals Corp. (www.aldacorp.com)
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCBB under the symbol APCSF.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Contacts:ALDA Pharmaceuticals Corp. - Sales ManagementDiane MannAccount Executive604-521-8300, Extension 4diane_mann@aldacorp.comALDA Pharmaceuticals Corp. - Sales ManagementAdriana CikojevicAccount Manager604-521-8300, Extension 6adriana_cikojevic@aldacorp.comALDA Pharmaceuticals Corp. - Sales ManagementTracy HaubrichAccount Manager604-521-8300, Extension 7tracy_haubrich@aldacorp.comMarketplace IGARetail Saleswww.marketplaceiga.com/locator.aspxAcklands-Grainger Inc.Commercial Saleswww.acklandsgrainger.comALDA Pharmaceuticals Corp.Scott YoungInvestor Relations604-377-5781 or 604-521-8300 Ext 8604-521-8322 (FAX)scott_young@aldacorp.comwww.aldacorp.com
SOURCE: ALDA Pharmaceuticals Corp.
mailto:diane_mann@aldacorp.com mailto:adriana_cikojevic@aldacorp.com mailto:tracy_haubrich@aldacorp.com http://www.marketplaceiga.com/locator.aspx http://www.acklandsgrainger.com mailto:scott_young@aldacorp.com http://www.aldacorp.com
Copyright 2009 Marketwire, Inc., All rights reserved.
Rage Against The Machine
Well I'll tell you, I eat properly when ever possible, take my various supplements, exercise a lot, get fresh air when ever I can and last but not least I have never had a flu shot and have never been sick. I've always been a little suspicious of the shot and even more so this year. Lots of conspiracy theories going around again this year and only time will tell if any of them have any credence. Of course that doesn't mean I won't try and capitalize on a new company or product lol. After all we are in this to make money are we not?
Rage Against The Machine
MILLION HIT BY 'PLAGUE WORSE THAN SWINE FLU'
http://cottontopssandbox.wordpress.com/2009/11/15/million-hit-by-plague-worse-than-swine-flu/
Rage Against The Machine
Surf: My answer to you post.
"Basically, though, I give my opinion, good or bad, depending on the situation, from the shareholder's point of view"
Yes you do and I always appreciate your input; sorry if I offended you in any way.
"Sometimes that matters to management (or insiders), sometimes it doesn't"
It rarely does unless you have enough shares and money to make them pay for their indiscretions.
"The insiders always have the advantage on when to sell!"
Absolutely, they always do; but there is nothing that we can do about it, except to ponder why they did and maybe put a positive spin on it if we feel strongly that there is one. If not nail them to the cross with whatever nails we can find.
"We don't have the advantage that insiders do."
That's right and we never will. Bottom line is if you own enough shares; sell some occasionally to boost your moral and live to compete another day. You can always buy them back.
Rage Against The Machine
Alda Soars on 2010 Olympic Contract as J&J Withdraws (Update2)
By Doug Alexander
Nov. 11 (Bloomberg) -- When Johnson & Johnson, maker of the Purell hand sanitizer, ended its run as a worldwide Olympic sponsor a year ago, Alda Pharmaceuticals Corp. saw a chance to fill the void.
Alda, with 10 employees in the Vancouver suburb of New Westminster, signed a contract in July to be the official supplier of hand sanitizers for the 2010 Winter Olympics. The stock has soared.
“That really gave us instant credibility,” Alda Chief Executive Officer Terrance Owen, 63, said in an interview. “That’s how the whole thing took off, and it’s snowballed from there.”
Alda more than doubled since July 15 and surged almost sixfold since the start of the year when the company traded at 11 cents. Alda fell 2 cents to 65 cents at the close of trading today on the TSX Venture Exchange in Toronto.
The T36 Antiseptic Hand Sanitizer was developed as a spinoff from the company’s disinfectants in April, when an outbreak of swine flu emerged in Mexico and the U.S. and started spreading. The H1N1 influenza has since become a global pandemic, creating a surge in demand for flu-prevention goods such as hand sanitizers.
Alda, a 13-year-old company that first sold shares to the public in 2003, has seen demand “increase dramatically” for its newest product, according to Owen. It signed a supply deal with Loblaw Cos.’s Asian grocery chain T&T Supermarket last month, and is seeking to put it in drug stores across Canada.
Doubled Staff
The company doubled its staff from a year ago, hiring three salespeople, a manager and administrative assistant. Alda is also seeking approval to sell the product outside Canada, in countries including Australia, the U.K. and the U.S.
Sales of hand sanitizers in the U.S. for the year ended Oct. 3 jumped 23 percent to $180 million from a year earlier, according to The Nielsen Co., which tracks consumer markets. In Canada, where hand sanitizers are a C$25 million ($23.7 million) business, sales are up 44 percent from a year ago, Nielsen said.
Messages left with Johnson & Johnson spokesman Marc Boston weren’t returned.
Alda, whose disinfectants were originally developed for hospitals, dental clinics and medical labs, is anticipating a “substantial” order tied to the Winter Olympics, held in Vancouver and Whistler starting Feb. 12. Games organizers may buy dispensers and bags, and “tens of thousands” of 60- milliliter (two-ounce) bottles to give away in gift packs for athletes, volunteers and the media, Owen said.
Canadian Roots
Alda’s British Columbia roots may have helped it win over Games organizers in getting the contract, he said. Alda makes its hand sanitizer at a plant in Surrey, which has ramped up production.
“The fact that we are local and small and use local suppliers and are nimble on our feet certainly was in our favor,” Owen said.
Alda aims to use that Olympic exposure, combined with the swine flu pandemic, to turn the money-losing business with a market value of C$33 million into a profitable company. Alda had a loss of C$1.18 million on revenue of C$282,261 for the year ended June 30, according to regulatory filings.
“We’re in the middle of a perfect storm here,” Owen said. “We just have to get our product out there and get it into as many hands as possible.”
To contact the reporter on this story: Doug Alexander in Toronto at dalexander3@bloomberg.net
Last Updated: November 11, 2009 16:26 EST
Rage Against The Machine
Holly man, don’t need Drumstick here these days lol.
Rage Against The Machine
Still not whet you are looking for; but still a good read with some of the stuff you are looking for such as projections on PPS and EPS.
Couldn't get the link to work so I copied and pasted everything.
Daegen View profile
More options Oct 19, 2:11 am
From: Daegen <dae...@gmail.com>
Date: Sun, 18 Oct 2009 23:11:25 -0700 (PDT)
Local: Mon, Oct 19 2009 2:11 am
Subject: The rising of MedaSorb.
Guys, have a read on this one, looks pretty interesting from here
onwards. There were charts and pipeline stages that weren't included.
As such please go through this link to view all in completion. Thanks
http://tapebeat.com/News/medasorb-draws-closer-to-completion-of-human...
When it comes to investing, everyone familiar with the biotech sector
is keenly aware that stocks of cancer related companies can be
significant investment opportunities if you manage to get in at the
right time. It’s all about timing. Well, we would like to bring you
all along on our journey, one where we will be highlighting a company
with an enormous potential, yet has been hidden away with very limited
exposure … until now. Ironically, it isn’t a company developing a
product with its primary focus being the treatment of cancer, but for
severe sepsis or “Overwhelming Infection”. Despite all of today’s
modern technology and even with the best in medical care sepsis kills
more people each year than any single form of cancer. It kills more
people than heart attacks and strokes. Globally, about 20 million
people a year develop sepsis and 1 out of every 3 dies from it. Many
of us have friends or family members that have been affected by this
horrible condition, and unfortunately there has not been any effective
treatment to date, neither drug nor device, until now. We can finally
see the light at the end of the tunnel and MedaSorb Technologies Corp.
(MSBT.OB) is leading the way.
Tapebeat, a news and research portal for the bio-tech sector in
association with the Farseers Group is proud to profile one of the
most exciting up and coming biotech companies, MedaSorb Technologies,
which is perfectly poised to realize exponential growth. MedaSorb
Technologies is a medical device company that operates exclusively
through its wholly owned subsidiary, CytoSorbents Inc. Their flagship
medical device, the “CytoSorb™”, is a patented blood purification
device that uses state of the art resin technology to remove toxins
from the blood, allowing the recirculation of clean blood back into
the body. While the technology is on the cutting edge, it has a low
cost to manufacture, a long shelf life, is easy to use, and is very
compatible with standard dialysis equipment. Unlike a drug, which can
have many adverse side effects, this device is very low risk, which
will benefit the company greatly during the CE mark and FDA approval
process. Medical devices have a very high rate of approval and with
shorter timelines, especially ones with a need as great as this.
There are two processes that contribute to onset of severe sepsis.
First, is either a bacterial or viral infectious trigger which
typically is treated with antibiotics or antiviral medications. The
second, which is the more damaging process, is the body’s abnormal
immune response to the infection. The body undergoes a massive
production of cytokines which causes what is called “cytokine storm”.
Cytokines are protein messengers that work to help ensure proper
function of the body’s immune system. The problem though is that
severe sepsis causes the body’s immune system to over-produce
cytokines in the extreme which leads to a very toxic state in the body
causing damage to cells, tissues, and organs. It is this “cytokine
storm” that is responsible for organ failure, immune system failure,
and death in patients with severe sepsis. Cytokine storm has also been
linked as a major driver behind death associated with certain virulent
strains of influenza such as avian (H5N1) and swine (H1N1) flu.
Severe sepsis is rising due to an aging population, an increase in
conditions like cancer and diabetes, the spread of antibiotic
resistant bacteria, and an increasing use of medical devices that are
prone to infection, like artificial knees, elbows, and hips. The
current swine flu pandemic has highlighted the serious lack of
effective therapies for critically-ill septic patients. It is clear
that better treatments are needed, such as the CytoSorb™ device, even
without major pandemic outbreaks or the threat of biological attacks.
From a cost control perspective there is a tremendous need for the
CytoSorb™ technology as sepsis costs the U.S. healthcare system about
$18 billion every year, making it one of the most expensive diseases
to treat.
MedaSorb is currently engaged in human clinical trials in Germany, and
have ramped up the number of test sites from three to up to twelve
recently. Germany is the largest medical device market in the European
Union and third in the world. To help fund and ensure the successful
number of participants in the study, they recently received a cash
infusion of $1.3M through an investor, who will be able to convert
warrants to common shares up to one year from then. This added
liquidity will be instrumental to helping ensure they are able to
achieve their goal by year’s end, and position them perfectly to
obtain CE Mark European approval. The best part about the financing is
that there is no immediate dilution of stock. The share count remains
extremely low at only 42M shares outstanding, with almost 40% owned by
insiders and 5% owners. The very low market cap (approx. $6.5M) and
float make this an ideal opportunity for significant gains in both the
short and long term.
Investors are anxious to know how the human trials are going and we
are hopeful we will get some insight at the upcoming 2009
International Sepsis Symposium to be held in Amsterdam, November
11-14. We expect a continual upward movement in the share price in the
coming days in anticipation of an update on the progress so far. Those
that go long will should be handsomely rewarded over the coming
months. We expect this stock to continue to grow more and more with
large inflection points at news on the progress of the trials,
successful completion in a few short months, at CE Mark approval,
announcement of production commencing, and at FDA approval. 2010 will
be an exciting year for MedaSorb.
Pipeline
MedaSorb Technologies has a stable of promising products in various
stages of development, as well as 26 issued patents and several more
pending. They have a distinct competitive advantage and have set
themselves up with protectionary measures to limit competition. The
following is a chart illustrating MedaSorb’s promising and robust
pipeline:
It is clear that MedaSorb has a rich pipeline and with a technology
that can easily be transferable to treat other diseases and
conditions. The sky is the limit with this type of technology. The
companies near term focus is achieving regulatory approval of
CytoSorb™ which is expected to be used for the treatment of severe
sepsis, cardiopulmonary bypass surgery, organ donation and drug
overdoses, all of which have a common theme, blood borne toxins. Its
proprietary polymer bead technology can be used for filtering toxins
from blood and physiologic fluids while allowing large essential blood
proteins to pass around the beads through the filter, back into the
patient.
The advantages of the Cytosorb™ technology are numerous, some already
mentioned.
- High gross margins at volume
- Works with standard dialysis equipment
- Specifically designed to remove a broad range of cytokines and
toxins making this the most logical strategy to treat cytokine storm
- Capable of removing up to 90% of certain cytokines from blood in a
single treatment
- In animal studies, significantly improved short and long-term
survival, hemodynamic stability and cytokine removal
- Very easy to use with a minimal learning curve and easy set up
- Compatible with blood as resin can come into direct contact without
material negative effects
- Since the Cytosorb™ does not have biological components it has a
long shelf life
- Passed extensive animal safety and ISO 10993 biocompatibility
testing.
- No serious device-related adverse events in more than 460 human
treatments with good tolerability and safety
- Low manufacturing risk as CytoSorb™ is manufactured and packaged
under strict, reproducible, well-documented guidelines in compliance
with FDA IDE standards
- Limited Competition as only Xigris (Eli Lilly) has been approved to
treat sepsis, but has questionable efficacy and safety
Management Team
MedaSorb Technology is run by a very experienced and accomplished
management team that knows what they are doing. Their motto is direct
and to the point: “Working to save Lives Through Blood Purification”.
So far they have acted in the best interest of their investor
community, looking for strategic alternatives to raise capital without
immediate and sizable stock dilution.
Phillip Chan, MD, PhD – Chief Executive Officer – is a Board-certified
internal medicine physician trained at Harvard and Yale Medical
School, a former Partner at NJTC Venture Fund and a co-founder of the
privately-held medical device firm, Andrew Technologies.
Robert Bartlett, MD - Chief Medical Officer - is world-renowned as the
pioneer in extracorporeal membrane oxygenation therapy (ECMO) and the
former Director of the Surgical Intensive Care Unit at University of
Michigan, with extensive experience in critical care medicine
including the treatment of sepsis and respiratory disease.
Vincent Capponi, MS - Chief Operating Officer - has more than 20 years
experience in the medical device, pharmaceutical and imaging fields at
Upjohn, Sims Deltec and Sabratek.
David Lamadrid, MBA - Chief Financial Officer - has over 17 years of
business experience in finance and management, previously at Chase
Manhattan Bank.
Valuation and Costing
At the recent 2009 Rodman & Renshaw conference, the company estimated
the severe sepsis market to be $8.8 Billion annually in the US and
Europe alone ($3.5B in US from 1 Million incidents (patients); $5.3 B
in Europe from 1.5 Million incidents annually). Clearly the worldwide
market would be significantly greater with about 20 Million incidents
annually. The CytoSorb™ blood purification process involves treating
for 6 hours a day for 7 days with a new CytoSorb™ cartridge each day
at a cost of $500 per cartridge for a total of $3,500. This is very
affordable for hospitals and patients, especially since sepsis patient
costs are normally more than $3,000 for each day in the intensive care
unit. If the CytoSorb™ treatment can speed recovery and get a patient
out of the intensive care unit just one day faster, it could
practically pay for itself. In addition to being a high profit margin
disposable, CytoSorb™ is compatible with standard hemodialysis
equipment found in any major hospital. This is very important in this
cost conscious environment, since hospitals won’t need to purchase any
additional equipment. The device can easily be run by a technician
familiar with dialysis, so no significant training is needed.
We have taken an extremely conservative approach and have only assumed
a small market penetration in just the US and EU in our valuation.
Expected PPS = ((Total Customer Base * Annual Revenue Per Customer *
Possible Market Penetration * Net Profit Margin) / Cost of Equity) /
Number of Outstanding Shares
Given the CEO of Medasorb stated that the incident(patients) rate is
approximately 2.5 Million/year with access to Cytosorb™ treatment.
The cost of the course of treatment per incident(per patient) as
explained above is $3,500
From the recent 10K filing and as of August 14, 2009 there were
41,520,427 common shares issued and outstanding.
At the time of this analysis the average Beta for MSBT is 1.35
The risk free rate is 0.0013. Used the 3 month T-bill rate from
Bloomberg.
The market’s historical excess return rate is 0.068.
Cost of Equity using the CAPM formula: (Beta * Market’s Historical
Excess Return Rate) + Risk Free Rate = Cost of Equity. The resulting
calculated Cost of Equity is 0.093
The Variables:
C: Total Potential incidents(US and Europe alone) = 2,500,000
R: Revenue Per Incident = 3,500
P: Potential Market Penetration = 0.03
(Just 3% Once again to err on the conservative side, note that there
are no therapies approved to specifically treat cytokine storm
directly because previous technologies have been inadequate)
N: Net Profit Margin = 0.25
(This is a very conservative percentage and the profit margins are
well around 40% on similar hemoperfusion charcoal cartridges used for
drug detoxification, which cannot efficiently remove cytokines)
E: Cost of Equity = 0.093
(The value of E at 0.093 can here be compared to a P/E ratio of 10.75
which is again very conservative number. P/E ratios historically
ranged between 10 to 20, 10 being undervalued)
S: Number of Shares = 41,520,427
The Formula:
Estimated PPS = ((C * R * P * N) / E) / S
Estimated PPS = ((2,500,000 * 3,500 * 0.03 * 0.25) / 0.093) /
41,520,427 = $16.98
Revenues= 2,500,000 * 3,500 * 0.03 = $262.5 M
EPS= 262.5*0.25 / 41.52 = $1.58
We believe these to be fair estimates based on real world information
for each of the variables in the equation. We then scaled the
variables to come up with a conservative estimate. This is not an
exact science, and some of the values could be quite different from
what we have decided to use. However, by making an effort to err on
the conservative side we can reduce the effect of errors that might be
introduced by potentially inflated numbers found in our research.
Again, this is just a conservative 3% of the market penetration from
the CEO’s forecast in the US and Europe markets, but we strongly
believe that this figure can easily be surpassed. Many of the EU
nations motivate and reward hospitals for expediting recuperation,
which enables savings for the Government.
The analysis based on just 3% market penetration can be treated as our
base line case. We have also assumed both more and less optimistic
views at 4% and 2% penetration respectively. We added a conservative
25% sales growth for 2011 for continuing penetration in the EU as well
as FDA approval and penetration in the US. Realistically it would be
much higher with US acceptance.
Assumptions for the Forecast:
Company succeeds in getting the European CE Mark and FDA approvals
Company doesn’t dilute the existing shares
No strategic alliances or partnerships (can have a dilutive effect on
profitability)
Revenue Forecast:
EPS Forecast:
Bottom line, with extremely conservative assumption we estimate the
potential price per share of $16.98, which should be enough risk vs
reward to entice any investor to buy at today’s significantly
undervalued price of about $0.20 cents per share! In investor speak
that’s a 113 bagger, or said another way a 11,233% increase!
Financial Status:
The Company ended the second quarter of 2009 with $1.4 million in cash
and on October 5, 2009, certain investors exercised warrants to
purchase an aggregate of 13,357 shares of Series B Convertible
Preferred stock at a purchase price of $100.00 per share. As a result
of the exercise of the warrants, the company received net cash
proceeds of $1.3 million. Again, we believe the company is in a good
financial position to comfortably finish the necessary trails and
submit an application for the European CE mark approval process by
2010.
The Company has a decent balance sheet for being in this stage of
development, with a low amount of liabilities (less than $1M). Many
small cap Bio-tech companies in the same stages seeking regulatory
approval are often in much worse shape, being burdened by a heavy debt
load.
From the most recent 10Q:
Conclusion:
Medasorb Technologies (MSBT) undoubtedly has the potential to be one
of the biggest return on investment plays in a long time in the
biotech industry. Similar companies namely Renal Solutions and
NxStageMedical with less revenue potential have a market
capitalization of close to 200 Million and higher. Many biotech
investors witnessed the amazing run of Nephros (NEPH) (a comparable
situation with much less market potential) as its share price went
from a low of $0.05 to as high as $2.50 in 4 short months recently. It
is rare to see small cap BioPharma companies with promising products
and low numbers of outstanding shares, while also having a strategy of
providing investor confidence by looking for other alternative ways of
raising capital vs just using dilution. MedaSorb is one such rare gem,
a big diamond in the rough, having only 42M total outstanding shares
with almost 40% held by insiders and 5% owners. The recent $1.3
million investment should be very reassuring to investors as it will
enable successful completion of the trials on time and at the level of
participation they need for CE mark approval by 2010.
The stock has been slowly gaining momentum, visibility and has
recently reached a new 52 week high, but has since settled back
slightly. The current share price is a very favorable entry point. Now
is a good time to capitalize on this before it’s too late and the
proverbial ship has set sail. With the potential multi-billion dollar
market, little to no competition for its products, and the current
market cap being only about $6.5M, we strongly believe that MedaSorb
Technologies (Symbol: MSBT) is extremely undervalued and is an
excellent compelling investment opportunity. Again, we expect an
upward trend in the share price in the coming days in anticipation of
news from the upcoming 2009 International Sepsis Symposium to be held
in Amsterdam, November 11-14, 2009.
In this Context we would like to point our readers to the below blog
on MedaSorb written by Jospeh Krueger, who is a senior scientist at a
major pharmaceutical company. Jospeh has a Ph.D in Cancer Biology and
performed post doctoral studies at the Scripps Research Institute and
UC San Diego. He has 10-15 peer reviewed publications in the cancer
field and has received multiple competitive grants for his scientific
research. His current position familiarizes him with drug discovery
and drug development in the pharmaceutical industry. As an active
industry scientist and skilled investor, we value his opinion and
would invite you to read his recent article:
BLOG: http://seekingalpha.com/instablog/492120-jospeh-krueger/31738-medasor...
Disclosure: This report is written and submitted by Farseers
Investment Group (www.farseers.com) members M. Rogaliner and V.
Nukala, who hold a Long Position in MSBT.
Press Releases:
MedaSorb Technologies Corporation to Present at the Rodman & Renshaw
Global Investment Conference
Tuesday August 18, 2009, 8:30 am EDT
Monmouth Junction, NJ--(August 18, 2009)--MedaSorb Technologies
Corporation (OTCBB:MSBT) and its wholly-owned subsidiary,
CytoSorbents, Inc., announced that Dr. Phillip Chan, Chief Executive
Officer, will present at the 11th Annual Healthcare Conference at the
Rodman & Renshaw Global Investment Conference in New York City. The
conference will take place at the New York Palace Hotel from September
9 to 11. http://www.rodmanandrenshaw.com/conferences?id=30
An audio webcast of the slide presentation will be available for 90
days after the event at http://www.wsw.com/webcast/rrshq15/msbt.ob
CytoSorbents, Inc. Comments on CytoSorb(TM) and the Swine Flu Outbreak
Wednesday May 6, 2009, 8:30 am EDT
MONMOUTH JUNCTION, NJ--(MARKET WIRE)--May 6, 2009 -- CytoSorbents,
Inc. comments on the current swine flu outbreak and highlights the
urgent need for improved therapies for influenza and other respiratory
viruses. In particular, potentially virulent pathogens such as avian
flu (H5N1 subtype), swine flu (H1N1 subtype), and the SARS virus can
quickly kill a large percentage of those infected. According to the
Centers for Disease Control, normal seasonal influenza afflicts 15-60
million people in the United States each year, hospitalizing more than
200,000, and directly contributing to the deaths of 36,000 people
annually. Although these numbers are significant, in contrast, the
1918 Spanish influenza pandemic infected an estimated one third of the
world population, killing nearly 50 million people. Highly virulent
flu strains have the ability to evade neutralization by the immune
system, leading to a prolonged and intense infection that can lead to
severe sepsis and death. Although the virus itself has destructive
capability, the body's own aggressive immune response and "cytokine
storm" are recognized as leading drivers of mortality in these
patients. Cytokines are normally helpful proteins that control the
immune system. In severe sepsis due to influenza, however, cytokines
are often produced in excessive, toxic quantities leading to acute
respiratory distress syndrome (severe lung inflammation), organ
failure, and numerous complications that often result in death. Anti-
viral therapy such as Tamiflu(TM), Relenza(TM) and amantadine may slow
viral infection if used early enough and if resistance is not an
issue. But given the major role that cytokine storm is believed to
play in the pathogenesis of these deadly viruses, more options are
needed to directly address this critical issue now.
CytoSorbents, Inc. Recognized as "Company Most Likely to Succeed" at
the 2009 New Jersey Venture Conference and Provides Clinical Update
Monday March 30, 2009, 1:13 pm EDT
MONMOUTH JUNCTION, NJ--(MARKET WIRE)--Mar 30, 2009 -- CytoSorbents,
Inc., the wholly-owned operating subsidiary of MedaSorb Technologies
Corporation (OTC BB:MSBT.OB - News), announced it was chosen as
"Company Most Likely to Succeed" by independent judges at the 2009 New
Jersey Technology Council Venture Conference on March 27, 2009. The
Company was one of 60 healthcare and technology companies presenting
at the conference who were eligible for this coveted all-around award.
"We feel extremely honored to have received this award, particularly
against such solid competition," stated Dr. Phillip Chan, CEO. "It is
especially gratifying that others recognize the significant value we
are building and the potential of our technology to treat severe
sepsis, one of the top medical causes of death in the world. We are
committed to increasing shareholder value by making significant
progress on key milestones and objectives, including our European
Sepsis Trial. Among other means, we will continue to foster increased
awareness of our Company through venues such as the New Jersey
Technology Council Venture Conference and the In3 West Conference that
we presented at in early March. Our story has been getting stronger
and has been well-received because it is based on compelling science
and our unique CytoSorb(TM) blood purification technology."
CytoSorbents provides the following clinical update on its current
European Sepsis Trial: -- Twenty-two patients have been enrolled to
date from three trial sites. -- Recruitment is now expected to
accelerate with a current total of ten initiated clinical sites. --
The CytoSorb(TM) treatment has been well-tolerated by patients and
easily administered by hospital staff on standard dialysis equipment.
-- There have been no serious device related adverse events associated
with CytoSorb(TM) treatment in more than 450 human treatments,
approximately 90 of which have been in septic patients. -- The Company
continues to expect trial completion in 2009 with the goal of CE Mark
approval and initial commercial sales in Europe next year.
MedaSorb Technologies Corporation Improves Balance Sheet
Tuesday February 3, 2009, 12:24 pm EST
MONMOUTH JUNCTION, NJ--(MARKET WIRE)--Feb 3, 2009 -- MedaSorb
Technologies Corporation (OTC BB:MSBT.OB - News) and its wholly-owned
subsidiary, CytoSorbents, Inc., announced that it was approved to
participate in the New Jersey Emerging Technology and Biotechnology
Financial Assistance Program and sold its net operating loss, netting
approximately $248,000 to the Company. This is in addition to the
$840,000 raised in the second close of the Series B financing in
August 2008, bringing the total amount of capital raised by the
Company to $5.5 million over the past 7 months.
"This further bolsters our balance sheet to facilitate the completion
of our European Sepsis Trial -- evaluating the treatment of patients
with severe sepsis and respiratory failure with our CytoSorb(TM) resin
cartridge," commented Dr. Phillip Chan, CEO. "Severe sepsis, often
called 'overwhelming infection,' is so prevalent that most people
unfortunately know someone who has died from this terrible disease.
CytoSorbents hopes to significantly impact the outcome of sepsis with
its unique treatment approach
About CytoSorbents and CytoSorb™
CytoSorbents, Inc, with its parent MedaSorb Technologies Corporation,
is in clinical trials to treat severe sepsis, often called
"overwhelming infection," with a novel blood purification device
called CytoSorb(TM). Severe sepsis is typically caused by bacterial
infections like pneumonia, or viral infections like influenza. It
afflicts more than 1 million people in the United States and an
estimated 18 million people worldwide each year, killing one in every
three patients despite the best treatment. In the United States, more
die from severe sepsis than from either heart attacks, strokes or any
single form of cancer. Much of the organ failure and mortality in
severe sepsis is caused by the abnormal massive production of
cytokines by the immune system, often called "cytokine storm." CytoSorb
(TM) is a cartridge containing highly porous polymer beads that are
designed to filter cytokines and treat potentially fatal cytokine
storm. As blood is pumped through the CytoSorb(TM) cartridge using
standard dialysis equipment, the beads bind and remove cytokines and
other toxins from blood. The treated blood is then returned to the
patient. The Company is currently conducting its European Sepsis Trial
-- a multi-center, randomized, controlled clinical trial using its
flagship CytoSorb(TM) device to treat up to 100 patients with severe
sepsis in the setting of respiratory failure. Pending a successful
trial, the Company will seek CE Mark approval and commercialization of
CytoSorb(TM) in the European Union in 2010. CytoSorb(TM) is one of a
number of different resins designed for different medical
applications, including improved dialysis, the potential treatment of
inflammatory and autoimmune disorders, treatment of rhabdomyolysis in
trauma, drug detoxification and others.
ADDITIONAL BACKGROUND INFORMATION ON SEPSIS IS AVAILABLE IN OUR
RESOURCE LINKS TAB AT THE TOP OF THE PAGE
Rage Against The Machine
MedaSorb Technologies (MSBT.OB) Draws Closer to Completion of Human Clinical Trials
10/19/2009 - Business Wire
Upcoming Conference
NEW YORK, Oct 19, 2009 (BUSINESS WIRE) --
TapeBeat.com, the news and research portal for the serious bio-tech investor in conjunction with the Farseers Group is proud to profile one of the most exciting up and coming biotech companies, MedaSorb Technologies (MSBT.OB), which is perfectly poised to realize exponential growth.
MedaSorb Technologies is a medical device company that operates exclusively through its wholly owned subsidiary, CytoSorbents Inc. Their flagship medical device, the "CytoSorb(TM)", is a patented blood purification device that uses state of the art resin technology to remove toxins from the blood, allowing the recirculation of clean blood back into the body. Globally, about 20 million people a year develop sepsis and 1 out of every 3 dies from it. Severe Sepsis may occur as a result of a bacterial or viral infectious trigger or may be caused by certain virulent strains of influenza such as avian (H5N1) and swine (H1N1) flu.
Earlier this year the number of trial sites for The CytoSorb(TM) treatment was increased in keeping with the company's goal to complete trial enrollment in 2009 then obtain CE Mark approval and initial commercial sales in Europe next year. Considering that the company has stated that treatment has been well-tolerated by patients and easily administered by hospital staff on standard dialysis equipment we are hopeful to get some insight at the upcoming 2009 International Sepsis Symposium to be held in Amsterdam, November 11-14. Anxious investors hungrily await.
The technology is on the cutting edge, it has a low cost to manufacture, a long shelf life, is easy to use, and is very compatible with standard dialysis equipment. Unlike a drug, which can have many adverse side effects, this device is very low risk, which will benefit the company greatly during the CE mark and FDA approval process. Medical devices have a very high rate of approval and with shorter timelines, especially ones with a need as great as this.
The complete research is available free at TapeBeat.com
TapeBeat.com is not a registered investment advisor nor compensated to report news about publicly traded companies. Information should not be construed as a recommendation. Farseers is a private Investors group. By viewing information on our site you agree to the disclaimer found therein.
SOURCE: TapeBeat.com
TapeBeat.com Philip Runfeldt, 800-856-8734 admin@tapebeat.com
Copyright Business Wire 2009
Rage Against The Machine
Wow! I leave for a few days and come back to find the lemmings jumping off the cliff; and why? Because of a couple of false assumptions made by some research company that I’ve never heard of. Also I’m thinking that maybe TapeBeat should have made sure that they were 100% accurate in their so called assumptions before putting out a release that might affect the share price of a company. Maybe call them and ask them if the release is accurate. Absolutely amazing. Nothing has changed with this company. They still have a great product. I hope all the lemmings can swim. Ok, my venting is done, on to something more productive, like unpacking.
Rage Against The Machine
I think what you are looking for is a little T.A. which I personally don't believe in when it comes to penny stocks. Read Chivito's post and get on board, as you may end up paying more than you would have liked.
Rage Against The Machine
I like the new site because what it says to me is that "Our products protect all people; but most importantly our children". Also adds a little lite heartedness to a very serious subject.
Rage Against The Machine
Good on you! I'm still waiting. I guess as the pigeon flies it makes sense; but then again maybe he dropped them into Lake Superior.
Rage Against The Machine
Checked the Acklands Grainger outlet in my area of Ontario and it is not listed in their product lines. Sent them an email a week ago asking why, which was to be answered in 24hrs. Still waiting to hear from them.
Rage Against The Machine
http://watch.ctv.ca/news/clip222799#clip222799
Rage Against The Machine
ALDA Enters Into Supplier Agreement With Acklands-Grainger Inc.
VANCOUVER, BRITISH COLUMBIA, Oct 08, 2009 (MARKETWIRE via COMTEX News Network) --
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCBB: APCSF) ("the Company" or "ALDA") announces that it has entered into a Supplier Agreement with Acklands-Grainger Inc.("AGI"). ALDA's products will be distributed through AGI's five distribution centres to its 160 branches across Canada and included in AGI's full catalogue of products. Dr. Terrance Owen, President & CEO states, "This agreement with AGI is an important step in achieving nation-wide distribution of our products. ALDA's status as an Official Supplier of the 2010 Winter Games has created a lot of opportunities for the Company, especially with other Official Suppliers, such as AGI. We look forward to forging other partnerships that are equally as important as this one."
About Acklands-Grainger Inc. (www.acklandsgrainger.com)
Acklands-Grainger Inc. is Canada's largest distributor of industrial, safety and fastener products with a comprehensive catalogue, 160 branches and 5 distribution centres across the country. Acklands-Grainger is the Official Supplier of the Vancouver 2010 Olympic Winter Games, Vancouver 2010 Paralympic Winter Games, the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for industrial safety and material handling supplies.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCBB under the symbol APCSF. The Company is the Official Supplier of the Vancouver 2010 Olympic Winter Games, Vancouver 2010 Paralympic Winter Games, the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Contacts:ALDA Pharmaceuticals Corp.Sales Management:Diane Mann, Account Executive604-521-8300diane_mann@aldacorp.comALDA Pharmaceuticals Corp.Sales Management:Adriana Cikojevic, Account Manager604-521-8300adriana_cikojevic@aldacorp.comALDA Pharmaceuticals Corp.Sales Management:Tracy Haubrich, Account Manager604-521-8300tracy_haubrich@aldacorp.comALDA Pharmaceuticals Corp.Scott YoungInvestor Relations604-377-5781scott_young@aldacorp.comwww.aldacorp.com
SOURCE: ALDA Pharmaceuticals Corp.
mailto:diane_mann@aldacorp.com mailto:adriana_cikojevic@aldacorp.com mailto:tracy_haubrich@aldacorp.com mailto:scott_young@aldacorp.com http://www.aldacorp.com
Copyright 2009 Marketwire, Inc., All rights reserved.
Rage Against The Machine
ALDA Enters Into Vendor Agreement With London Drugs
VANCOUVER, BRITISH COLUMBIA, Oct 05, 2009 (MARKETWIRE via COMTEX News Network) --
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCBB: APCSF) ("the Company" or "ALDA") announces that it has entered into a Vendor Agreement with London Drugs Limited and the first order has been shipped. ALDA's products will be distributed through 70 stores operated by London Drugs in all four Western provinces. Dr Terrance Owen, President & CEO states, "This agreement with London Drugs is a very important step in achieving distribution of our products to consumers. Their stores draw huge numbers of customers every day and this traffic will give ALDA's products a tremendous boost. As the flu season and the H1N1 pandemic approach, ALDA and London Drugs will be in the forefront helping to keep people healthy."
About London Drugs (www.londondrugs.com)
London Drugs began its pharmacy business in Vancouver in 1945. Over the years, new departments were added, including cameras, small appliances, consumer electronics, computing equipment and software, pharmaceutical counseling, cosmetics, groceries, insurance and travel services. London Drugs now has 70 stores located in British Columbia, Alberta, Saskatchewan, and Manitoba with more than 6000 staff.
About ALDA Pharmaceuticals Corp. (www.aldacorp.com)
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCBB under the symbol APCSF.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Contacts:ALDA Pharmaceuticals Corp.Sales Management:Diane Mann, Account ExecutiveOffice: 604-521-8300 Ext. 4 or Cell: 604-657-0369diane_mann@aldacorp.comALDA Pharmaceuticals Corp.Sales Management:Adriana Cikojevic, Account ManagerOffice: 604-521-8300 Ext. 4adriana_cikojevic@aldacorp.comALDA Pharmaceuticals Corp.Sales Management:Tracy Haubrich, Account ManagerOffice: 604-521-8300 Ext. 4tracy_haubrich@aldacorp.comLondon DrugsRetail Sales(http://www.londondrugs.com/Cultures/en-US/StoreLocator.htm)Eastern Esthetics (ON, QU, NB, NS, PE, NL)Retail Sales902-450-2161LCN Canada - West (MB, SK, AB, BC, NW, YK)Retail Sales780-462-2580ALDA Pharmaceuticals Corp.Scott YoungInvestor Relations604-377-5781scott_young@aldacorp.comwww.aldacorp.com
SOURCE: ALDA Pharmaceuticals Corp.
mailto:diane_mann@aldacorp.com mailto:adriana_cikojevic@aldacorp.com mailto:tracy_haubrich@aldacorp.com http://www.londondrugs.com/Cultures/en-US/StoreLocator.htm mailto:scott_young@aldacorp.com http://www.aldacorp.com
Copyright 2009 Marketwire, Inc., All rights reserved.
Rage Against The Machine
Good stuff Surf! I don't go there much anymore as I don't have time to sift through the garbage for the various stocks that I own/trade. Too busy enjoying the summer sunshine also. Again thank you and enjoy the rest of the summer and here's to some great NRs this coming Fall.
Rage Against The Machine
Stem Cell Therapeutics Corp. Announces Enrollment of First Patient in the modified REGENESIS Phase IIb Stroke Trial
CALGARY, ALBERTA, Aug 11, 2009 (MARKETWIRE via COMTEX News Network) --
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: SSS) is pleased to announce the enrollment of the first patient in its modified REGENESIS Phase IIb acute ischemic stroke trial. The modified REGENESIS trial is a double-blind, randomized, placebo-controlled Phase IIb clinical trial for SCT's lead program, NTx(R)-265, for the treatment of acute ischemic stroke. This first patient was enrolled by the clinical team of Dr. Vijaya Pamidimukkala from the Lalitha Super Specialties Hospital Pvt Ltd in Guntur, Hyderabad, A.P. Co-lead investigators for the modified REGENESIS Phase IIb trial are Dr. Steven C. Cramer of the University of California, Irvine, and Dr. Michael D. Hill of the Foothills Hospital at the University of Calgary.
Dr. Alan Moore, President and CEO, commented as follows:
"We are very happy to have begun recruiting the modified Phase IIb REGENESIS stroke trial. We have great expectations that this Phase IIb acute ischemic stroke trial will continue to build upon the positive clinical data available to-date, specifically the exciting results highlighted by the meta-analysis as announced on July 27th. Trial completion for the modified Phase IIb clinical stroke trial is anticipated for the end of calendar year 2009, allowing top-line data to be available by the end of Q1 09."
The modified REGENESIS Phase IIb acute ischemic stroke trial will be a multi-site trial, projected to enroll 128 patients at sites located in India, Canada and the U.S.
Additionally, the early warrant exercise incentive program which was announced on July 8th has since closed and is no longer available.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:Stem Cell Therapeutics Corp.Alan Moore, PhDPresident and CEO(403) 245-5495 ext.224Email: amoore@stemcellthera.comStem Cell Therapeutics Corp.Chloe Douglas-CramptonInvestor Relations(403) 245-5495 ext. 221Email: crampton@stemcellthera.comWebsite: www.stemcellthera.com
SOURCE: Stem Cell Therapeutics Corp.
mailto:amoore@stemcellthera.com mailto:crampton@stemcellthera.com http://www.stemcellthera.com
Copyright 2009 Marketwire, Inc., All rights reserved.
Rage Against The Machine
Nice article and a good site for stock info.
http://seekingalpha.com/instablog/444928-mike-perras/21680-canadian-stock-alerts-alda-pharmaceuticals-corp
Thanks for the posts Joda. I was beginning to think that jc and myself where the only ones interested in this stock lately. It has been quietly moving upward for the past three months; so there must be something good happening behind the scenes.
Rage Against The Machine
ALDA Pharmaceuticals Increases Private Placement
VANCOUVER, BRITISH COLUMBIA, Jul 17, 2009 (Marketwire via COMTEX News Network) --
ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) (the "Company") announces that the private placement disclosed in a new release dated July 3, 2009 of up to 3 million common share and warrant Units of the Company at a price of $0.20 per Unit has been terminated and that the Company will instead proceed with an offering of up to 6 million Units at a price of $0.25 for proceeds up to $1,500,000. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.40 per common share for a period of twelve (12) months from the date of the issuance of the purchase warrant with a forced exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.80 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days.
The offering is being made on a private placement basis pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange. All securities issued will be subject to a four-month restricted period and will bear a restrictive legend accordingly. Net proceeds from the offering will be used for working capital.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCBB under the symbol APCSF.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
The Units, Common Share, Warrants and the common shares issuable upon exercise of the Warrants have not been registered under the United States Securities Act of 1933 (the "Act") and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
SOURCE: ALDA Pharmaceuticals Corp.
ALDA Pharmaceuticals Corp.Diane MannDistribution & Sales Contact(604) 657-0369diane_mann@aldacorp.comwww.aldacorp.comRetail SalesEastern Esthetics (ON, QU, NB, NS, PE, NL)902-450-2161Retail SalesLCN Canada - West (MB, SK, AB, BC, NW, YK)780-462-2580ALDA Pharmaceuticals Corp.Scott YoungInvestor Relations Contact604-288-7222syoung@freeformcom.com
Copyright (C) 2009 Marketwire. All rights reserved.
Rage Against The Machine
I believe you are right SurfinNj, so around noon I finally convince myself that it was the right thing to do, and pressed the buy for a few more thousand shares. I believe strongly in this company and I truly believe that I will be rewarded in time for that belief; although there is a lot of gut feeling going on here as well. Oh and I also checked with my friends over at Agoracom first Drummer. lol
Rage Against The Machine
Another good link.
http://www.vancouver2010.com/en/news/news-releases/-/32566/18rn367/index.html
Rage Against The Machine
Got this from another site for anyone interested.
http://www.ctv.ca/servlet/an/local/CTVNews/20080124/BC_Vid_Newscast_080124/20080205/?hub=BritishColumbiaHome
Choose the newslink CTV News at Six for Wednesday, July 15
Starts at 11:48.
You can see the T36 label and TO speaking.
The news leads into this story after doing an H1N1 story by saying the Olympics brought in ALDA to help with fears of an H1N1 pandemic during the 2010 Winter Olympics.
Rage Against The Machine
This is in your face advertising to the world at very little cost. I don't know about you Drummer; but I'm just a little bit imprest with this news release.
Rage Against The Machine
ALDA Pharmaceuticals Corp. Named Official Supplier for the 2010 Winter Games
VANCOUVER, BRITISH COLUMBIA, Jul 15, 2009 (Marketwire via COMTEX News Network) --
ALDA Pharmaceuticals Corp. ("ALDA") (TSX VENTURE:APH)(OTCBB:APCSF) is partnering with the Vancouver Organizing Committee for the 2010 Olympic and Paralympic Winter Games (VANOC) to keep venues healthy and sanitized as the exclusive Official Supplier of hand sanitizer and disinfectant cleaning products for the Games.
The company, founded in 1996, publicly listed in 2003 and based in New Westminster, British Columbia, develops, manufactures and markets a family of proprietary infection control products based on its patented technology called T36(R). Under the agreement with VANOC, ALDA will make a financial investment in the Games and provide antiseptic hand sanitizer and handwipes, cleaning products and a hospital-grade spray disinfectant to the Organizing Committee. The hand sanitizer and handwipes will be available at competition and non-competition venues, including the Olympic/Paralympic Villages, polyclinic centres and food preparation areas.
In return, ALDA will have exclusive rights as an Official Supplier in the Hand Sanitizer and Disinfectant Cleaning Products product category for the 2010 Winter Games and rights to associate with the Canadian Olympic Team competing at the Vancouver 2010 Olympic Winter Games and the London 2012 Olympic Games.
"Our company is excited to play a role in helping ensure the 2010 Winter Games are among the healthiest ever held for athletes, spectators, volunteers and workers," said Terrance G. Owen, president and CEO of ALDA Pharmaceuticals Corp. "The Games are a perfect event to put our new consumer products, such as our antiseptic hand sanitizer, literally in the hands of potentially tens of thousands of people from around the world and help ensure the only things they take away from the Games are fun and memorable experiences."
"We're pleased to welcome this growing British Columbian company to the Vancouver 2010 team," said John Furlong, VANOC Chief Executive Officer. "We look forward to working with ALDA Pharmaceuticals and using their innovative line of sanitizing products to help us deliver great Games when we welcome the world in 2010."
British Columbia Premier, Gordon Campbell, added, "Strong partnerships are critical as we prepare to welcome the world in 2010. When thousands of athletes, teams, journalists and visitors come here to experience our province and the Vancouver 2010 Olympic and Paralympic Winter Games, this partnership will help to ensure their health and safety."
Compared to typical alcohol-based hand sanitizers, ALDA's antiseptic hand sanitizer has two active ingredients that provide faster action against a broader range of infectious organisms, including Norwalk-like viruses and that offer a long-lasting residual effect.
The company's hospital-grade disinfectant spray has been tested on more than 25 clinically important bacteria, viruses and fungi, and is approved for hospital use by Health Canada and the Canadian Food Inspection Agency (CFIA) for restaurants and the food processing industry. The spray kills infectious organisms such as polio, HIV and tuberculosis.
"VANOC takes our responsibility to ensure the Games are a healthy and safe place for all involved very seriously," said VANOC's chief medical officer, Dr. Jack Taunton. "ALDA is a great partner for the Games - it has undergone rigorous independent testing of its products and has been recognized by both Health Canada and the CFIA."
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. T36(R) has been proven effective against H1N1. The company trades on the TSX Venture Exchange under the symbol "APH", and is quoted on the OTCBB under the symbol "APCSF".
About VANOC
VANOC is responsible for the planning, organizing, financing and staging of the XXI Olympic Winter Games and the X Paralympic Winter Games in 2010. The 2010 Olympic Winter Games will be staged in Vancouver and Whistler from February 12 to 28, 2010. Vancouver and Whistler will host the 2010 Paralympic Winter Games from March 12 to 21, 2010. Visit www.vancouver2010.com.
VANOC's marketing program is focused on securing mutually rewarding partnerships with shared values to generate sufficient revenue to host successful Winter Games in 2010 and to leave a financial legacy for sport. VANOC's worldwide TOP Partners include Coca-Cola, Acer, Atos Origin, General Electric, McDonald's, Omega, Panasonic, Samsung and Visa. VANOC's National Partners are Bell Canada, Hudson's Bay Company, RBC Financial Group, General Motors of Canada, Petro-Canada and RONA.
VANOC's Official Supporters include Air Canada, BC Hydro, Bombardier, the British Columbia Lottery Corporation, Canadian Pacific, Insurance Corporation of British Columbia (ICBC), Jet Set Sports, Ricoh Canada, Royal Canadian Mint and Teck Resources. VANOC's Official Suppliers are 3M, Acklands-Grainger, Aggreko, ALDA Pharmaceuticals Corp., Aquilini Investment Group, Birks, Britco, Canada Post, Canwest Publishing, COLD-FX, Deloitte, Dow Canada, EPCOR, Garrett Metal Detectors, General Mills, Hain Celestial Canada, Haworth Canada, Karl's Global Events Inc., Jackson Triggs, La Presse, Millennium Development Corp., Molson, Nortel, Offsetters, Port Metro Vancouver, Purolator Courier Ltd., Saputo, Sleep Country Canada, Sun Microsystems of Canada, The Globe and Mail, Tickets.com, TransCanada, Vancouver Airport Authority, Weston Bakeries, Workopolis and Wrigley Canada.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming" and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
SOURCE: ALDA Pharmaceuticals Corp.
VANOC CommunicationsJason MacnaughtonVANOC Media Contact604.403.2734jason_macnaughton@vancouver2010.comwww.vancouver2010.comALDA Pharmaceuticals Corp.Scott YoungInvestor Relations Contact604-288-7222syoung@freeformcom.comwww.aldacorp.com
Copyright (C) 2009 Marketwire. All rights reserved.
Rage Against The Machine
ALDA Receives US Patent No. 7,560,422 for T36(R)
VANCOUVER, BRITISH COLUMBIA, Jul 14, 2009 (Marketwire via COMTEX News Network) --
ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) ("ALDA") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent Number 7,560,422 today. The patent is a continuation of US Patent Number 7,338,927 that was issued on March 4, 2008 and provides further protection for ALDA's T36(R) formulation until August 20, 2022. The new patent includes claims to additional aspects of the T36(R) formulation, including the use of T36(R) as a component of a personal lubricant, in a method of preventing or reducing the transmission of sexually transmitted diseases including Herpes, Chlamydia and HIV and for use in sanitizers and cleansers in creams, ointments and wipes.
Dr. Terrance Owen, President & CEO, states, "Issuance of this new US patent is an important step for ALDA because it provides protection for T36(R) for certain therapeutic uses. This ties in well with our strategy of registering T36(R) for therapeutic applications and provides a complement to the new PCT application which is in progress and covers more broad ranging therapeutic applications."
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCBB under the symbol APCSF.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
SOURCE: ALDA Pharmaceuticals Corp.
ALDA Pharmaceuticals Corp.Diane MannDistribution & Sales Contact(604) 657-0369diane_mann@aldacorp.comwww.aldacorp.comRetail SalesEastern Esthetics (ON, QU, NB, NS, PE, NL)902-450-2161Retail SalesLCN Canada - West (MB, SK, AB, BC, NW, YK)780-462-2580ALDA Pharmaceuticals Corp.Scott YoungInvestor Relations Contact604-288-7222syoung@freeformcom.com
Copyright (C) 2009 Marketwire. All rights reserved.
Rage Against The Machine
Here's hopping for a better week and some Earth shattering news this coming month. For now I sit and wait and trade other stocks. VSTN has been a money maker for me. Only good for those that have the stomach to play chapter 11 stocks.
Rage Against The Machine
APH: Manufacturing and sales agreements and Patents
On November 13, 2003, ALDA Pharmaceuticals Corp., formerly Duft Biotech Capital Ltd., completed the acquisition
of the assets of 513947 BC Ltd., formerly ALDA Pharmaceuticals Inc., (“the Qualifying Transaction”) and a $1.2 Million
financing arranged by Canaccord Capital Corporation (“the Financing”).ALDA trades on the TSX Venture Exchange
in Vancouver, Canada under the symbol “APH” and on the OTC BB under the symbol “APCSF”.
ALDA has developed a patented infection control formulation, referred to as T36®, a mixture of ethanol,
o-phenylphenol, benzalkonium chloride and other ingredients (including lemon fragrance and water). All of these
component chemicals are bio-degradable.
Manufacturing and sales agreements
Canada
On October 4, 2005 the Company signed a manufacturing agreement with Norwood Packaging Ltd. (“Norwood”)of
Surrey British Columbia, Canada to manufacture its T36® Disinfectant antibacterial product. On June 18, 2008, both
the Company and Norwood agreed to waive the 90-day notice period required in the agreement and to terminate the
agreement. For future orders, ALDA will provide Norwood with purchase orders and pay Norwood according to the
standard payment terms that Norwood provides to its other customers. The Company has also started to use other
manufacturers and, on February 23, 2009, the Company entered into a non-binding Letter of Intent to purchase all of
the business and undertakings of a pharmaceutical manufacturing firm.
An agreement between Group 270 Sales and Marketing Inc. (“Group 270”) and ALDA was established on November
17, 2006 in which Group 270 will assist ALDA in selling ALDA’s products in the retail market. To accomplish this,
Group 270 will undertake market research and a competitive analysis to estimate total annual volume in the area of
personal disinfectants, estimate annual sales volumes, establish the pricing structure for retail and establish a roll out
strategy to national retail chains, such as Shoppers DrugMart, Loblaws,Wal-Mart and Zellers, sourcing and engaging
a third party logistics company for order fulfillment, establish EDI and order processing development.
On August 22, 2008 Group 270 and the Company mutually agreed that Group 270 will be compensated at the rate of
$100 per hour rather than receiving a monthly retainer. In the event that both ALDA and Group 270 mutually agree
that there is sufficient reason to continue the payment, it will remain in effect on a month to month basis until the
payment of a commission rate of 8% of net sales exceeds the $1,500 per month. At that time the monthly payment will
cease and Group 270 will receive only the commission.
The agreement may be terminated if either party provides the other party with 60 days written notice, by either party if
there has been a breach of any provision of the agreement and thirty (30) days has elapsed from the date that written
notice has been sent to the party in breach by the other party or at the option of either party, if the other party becomes
insolvent; violates the laws, regulations, rules, or statutes of any government; ceases doing business; makes an
assignment for the benefit of creditors; or commits an act of bankruptcy. A failure by either party to exercise any right
hereunder shall not operate as a waiver of such right and all remedies contained within the agreement shall be
cumulative.
China
On October 6, 2004, ALDA entered into an agreement with Fuzhou Xinmei Biotech Co. Ltd. (“Fuzhou”) to
manufacture and distribute ALDA’s products Fujian province in China. On August 31, 2006, an agent actingon behalf
of Fuzhou (“the Agent”), received a Certificate of Approval from the Fujian Centre of Disease Control for T36®
Disinfectant after the product passed all of the required tests. The registration of T36® Disinfectant in China was
expanded beyond disinfection of inanimate objects, such as hospital equipment and instruments, to also allow external
use on humans, including use as a first-aid antiseptic and hand sanitizer. The Certificate of Approval allowed the
Agent to apply to the Chinese National Centre for Health Inspection and Supervision for approval to manufacture T36®
Disinfectant for sale in China and for export. On April 19, 2007, a manufacturing certificate (Certificate of Approval
(Health ID. No. 0109) was granted to the Agent in China for a period of four years from April 19, 2007 to April 18,
2011 and is renewable by filing an application for renewal 6 months before the expiry date.
In May 25, 2007, ALDA’s agent in China established a new company, He-Yi She Ye Limited (“He-Yi”)and the
agreement with Fuzhou was transferred to He-Yi and expanded to cover marketing in all of China. The agreement with
He-Yi provides that ALDA will provide He-Yi with all information that ALDA has at its disposal to assist with the
registration of ALDA’s products in China. In the agreement, it is stated that He-Yi would be responsible for procuring
all necessary government approvals for ALDA’s products within 6 months from the time all technical data to support
the application is provided by ALDA Pharmaceuticals Corp. Quarterly reports on the progress of the approvals were to
be provided to ALDA by He-Yi. Extensions could be requested by He-Yi to procure all necessary government
approvals and would not be unreasonably refused by ALDA for recurring periods of 3 months if He-Yi was employing
its best efforts in obtaining the registration of the ALDA products in China and was providing quarterly reports as
required or if more time was required by ALDA Pharmaceuticals Corp. to obtain information required by He-Yi. As
noted above, He-Yi has now fulfilled its obligations to register T36® Disinfectant for sale in China.
Under the terms of the agreement, ALDA Pharmaceuticals Corp. was to provide He-Yi with the specifications
required for He-Yi to provide a manufacturing facility suitable for the manufacturing of ALDA’s products.He-Yi was
to provide a fully equipped manufacturing facility according to the specifications provided by ALDA and to produce
the ALDA products subject to He-Yi employing its best efforts to obtain the space, materials and equipment specified
by ALDA. He-Yi has the right to distribute ALDA’s products in China subject to ALDA’s approval of each
distributorship. As announced in a news release distributed by the Company on May 29, 2008, He-Yi has fulfilled its
obligation to establish a manufacturing facility.
The Agreement is effective until April 18, 2011 (“the Initial Term”).Upon expiration of the Initial Term, the
Agreement may be renewed for additional periods, (“the Renewals”) provided that ALDA and He-Yi have each met
all of their obligations under the Agreement and provided that He-Yi is able to obtain renewals of the Certificate of
Approval (Health ID. No. 0109) that has been granted by the Ministry of Health of the People’s Republic of China and
expires on April 18, 2011. Any renewals will reflect current market conditions in the territory served by He-Yi at the
time the Renewals are granted and the time periods of any Renewals will be the same as the corresponding time
periods of the renewals of the Certificate.
For the first 3 years after production is started by He-Yi and within 6 months after production is started by He-Yi,
ALDA and He-Yi are to establish minimum sales levels and, thereafter, after each new distributorship is established.
He-Yi will pay ALDA a royalty, based on the gross revenues received by He-Yi for all of ALDA’s products sold in
China as follows:
5% during the first and second year after production is started by He-Yi,
8% during the third year,
6% after a doubling of sales over the sales achieved in the second year has occurred.
He-Yi will pay ALDA a 10% royalty based on the gross revenues received by He-Yi for all of ALDA’s products
sold by He-Yi outside of China.
All royalties will be paid monthly within 30 days after each month end.
ALDA, at ALDA’s discretion, will have the right to buy product from He-Yi. At the request of ALDA and with the
authorization of ALDA, He-Yi agrees to direct ship ALDA’s products for ALDA, at ALDA’s expense, to anywhere in
the world.
As of the date of this report, the agreement is in good standing. On April 8, 2008, the Company announced that He-Yi
had secured four contracts for the distribution of T36® Disinfectant in China. Evergreen Health Care committed to
minimum sales of 1 million RMB in Hong Kong and Macau for a period of one year, Jin Wei Kai Medical
Technology Limited and Jin Qin Scientific Development Ltd. to 4.8 Million RMB each over three years in northern
China (Beijing) and central China (Wu Hang), respectively, and Wondfo Biotech Co. Ltd. to 3 million RMB in
southern China (Guang Zhou) over three years. The total sales potential of all four contracts is 13.6 Million RMB or
nearly CDN $2 million at the current exchange rate. The Company will realize a royalty as described above on any
sales achieved by He-Yi. On May 29, 2008, the Company announced that the manufacturing facility set up in China
by He-Yi was operational and that the first production runs had started. In addition, a pilot batch of the T36®
formulation that was manufactured by He-Yi passed the quality control and efficacy tests. As of the date of this report,
the agreement is in good standing.
United States
On December 13, 2007, the Company announced that the services of Brand Institute, Inc. had been engaged to assist
with marketing efforts in the US and internationally, particularly with the development of the retail and therapeutic
applications of the T36® technology. The Company saw a need to align its marketing efforts with its anticipated
European and FDA product registrations and the proposed listing of its shares in the US. Due to its US and
international presence, Brand Institute, Inc. was selected to work with the Company in its targeted markets. Brand
Institute, Inc. offers pharmaceutical naming, packaging and labeling, trade marking and market research services, as
well as global regulatory insight provided by former key officials from the FDA and Health Canada. With offices in
the US, Europe and Asia, Brand Institute Inc. will provide strategic and regulatory assistance to the Company as it
establishes its presence in markets outside of Canada. Brand Institute is also assisting the Company with the re-design
of its website and with other aspects of its retail marketing program, such as label design and graphics.
No other active sales or manufacturing agreements are in place.
Patents
The Company is attempting to patent or secure proprietary protection for the specific combination and manufacturing
of the T36® formulation although the ingredients are all common chemical compounds.
The Patent Cooperation Treaty (PCT) is an international patent law treaty established in 1970. It provides a unified
procedure for filing patent applications to protect inventions in each of its Contracting States, which includes each
jurisdiction specified below. A patent application filed under the PCT is called an “international application” or “PCT
application”. A single filing of an international application is made with a Receiving Office (RO) in one language. It
then results in a search being performed by an International Searching Authority (ISA), accompanied with a written
opinion regarding the patentability of the invention which is the subject of the application. Optionally, this is followed
by a preliminary examination, performed by an International Preliminary Examining Authority (IPEA). The PCT does
not lead to the grant of an "international patent", which does not exist, but rather, national patent examinations that are
handled by each relevant national or regional authority. For example, in Canada, the US, China, Australia and
Singapore, there are national patent offices whereas, in Europe, the European Patent Office handles the national phase
for its member states.
API filed patent application #PCT/CA2002/001284, “A wide spectrum disinfectant”, on August 20, 2002. All rights to
the patent application were transferred from API to the Company on completion of the Qualifying Transaction on
November 13, 2003. A summary of subsequent events is presented below.
Canada
assigned it Patent Application Number 2,495,938. On August 17, 2007, the Company filed a Request for Examination
with CIPO. On September 24, 2007 the Company filed a Voluntary Amendment to the patent application filed with
CIPO. The proposed amendments expanded the claims to include a number of therapeutic applications of the T36®
formulation, including its use in cosmetics and in a microbicidal gel to prevent the transmission of sexually
transmitted infections (“STI’s”). On October 4, 2007, the Company was notified that CIPO had acknowledged a
request by the Company to examine the patent application. Since the process of examination can take two years, for a
fee of $500, the Company requested an Expedited Examination on November 7, 2007 to reduce the response time to
approximately three months. On April 8, 2008, CIPO provided an Office Action in which a number of questions were
posed to the Company. Many of the same questions had already been posed by the Examiner for the EPO and the
Company was advised that a response was required by October 8, 2009. On the advice of the Company’s patent
lawyers, the Company decided to temporarily abandon the Canadian patent application and the abandonment was
deemed effective by CIPO on October 8, 2008. However, the patent application can be reinstated by October 8, 2009
by paying a fee of CAN$200.00 and submitting a response to the Office Action to CIPO. This decision was made to
defer the costs of the Canadian patent application for a period of one year at little cost.
European Union
On March 30, 2005 the PCT application was accepted for national examination by the European Patent Office (“EPO”)
which assigned it Patent Application Number 02754054.1-2113. The countries covered by the European patent
application are Austria, Belgium, Bulgaria, Switzerland, Cyprus, the Czech Republic, Germany, Denmark, Estonia,
Spain, Finland, France, Great Britain (the UK), Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco,
Netherlands, Portugal, Sweden, the Slovak Republic and Turkey. On May 18, 2005, the bibliographic data of the
above-noted application was published in the European Patent Bulletin, under Publication No. 1530485. The resulting
effect of such publication is that any possible infringer is deemed to have knowledge of the patent application without
the Company having to formally inform them of this application’s existence. On October 18, 2006 the EPO provided
the Company with an Office Action requesting further information on the patent application. The Company responded
to the questions and received a second Office Action, dated September 5, 2007 from the EPO. This second Office
Action requested that the Company provide certain additional information and to conduct certain experiments to
support the claims that were made in the application. The Company completed both the literature research and the
laboratory studies and, on December 19, 2008, submitted the response to the second Office Action to the EPO. A
response from the EPO is still pending.
China
On June 25, 2005 the Company was notified that the PCT application was accepted for national examination by the
Patent Office of the People’s Republic of China (“Chinese Patent Office”) and assigned Patent Application Number
02829642.7. On August 11, 2005, the Chinese Patent Office accepted a Request for Substantive Examination from the
Company. The application was published in the Chinese Patent Gazette on October 19, 2005, under Publication No.
CN1684711A and entered into Substantive Examination. On February 5, 2006, the Company filed a Voluntary
Amendment to the original patent application to correct certain minor errors in the original application. On June 2,
2006, the Chinese Patent Office provided an Office Action which requested certain additional amendments to the
patent application. On December 18, 2006, the Company filed its response to the Office Action. The Company was
notified by the Chinese Patent Office that the Chinese patent had been allowed, effective June 8, 2007. Amendments to
the original patent application were then drafted by the Company. As in the case of the amendments prepared for CIPO,
the proposed amendments to the Chinese patent expand the original claims to include a number of therapeutic
applications of the T36® formulation, including its use in cosmetics and in a microbicidal gel to prevent the
transmission of sexually transmitted infections (“STI’s”).On October 10, 2007, the Company was advised that the
amended claims had been submitted to the Chinese Patent Office. On January 30, 2008 the Chinese Patent office
assigned Chinese Divisional Patent Application No. 200710142798.3 to the new application which was
published in the Chinese Patent Gazette, under Publication No. CN101112624A. At the time of this report, no
further developments have occurred with this Chinese patent application. On February 6, 2008, the Company
announced that Certificate of Invention Patent Number ZL02829642.7 had been issued by the State Intellectual
Property Office of the People’s Republic of China. The patent provides protection for the composition and production
methods for ALDA’s T36® formulation until August 20, 2022.
United States
US Patent #7,338,927
On February 18, 2005, the US Patent and Trademark Office (“USPTO”) received the PCT patent application and
assigned it Patent Application Number 10/525,110. The patent application was published by the USPTO on December
22, 2005, under Publication Number US 2005/0282727. On July 27, 2006, the Company received that first Office
Action from the USPTO which required clarification or modification of certain claims made in the patent application.
The Company was required to respond to the Office Action by October 27, 2006 and did so on October 26, 2006 with
amendments to the claims that required clarification or modification. On February 7, 2007 the USPTO provided the
Company with a Notice of Allowance for the US patent with all claims made by the Company accepted by the USPTO.
A Notice of Allowance is not a grant of a patent and is subject to withdrawal by the USPTO or on petition by the
Company. The Company then filed certain minor, voluntary amendments to the patent application and a second
Notice of Allowance, dated June 8, 2007 was provided by the USPTO. On February 15, 2008, the Company was
advised that a Notice of Allowance had been received from the USPTO projecting that the US patent would be issued
on March 4, 2008. As scheduled, U.S. Patent Number 7,338,927 was issued on that date and provides protection for
the composition and production methods for ALDA's T36® formulation until August 20, 2022. The patent can be
viewed on the website of the USPTO.
U.S. patent application (Serial No. 11/966,128)
Amendments to the original patent application were drafted by the Company and submitted to the USPTO as a U.S.
Continuation Patent Application in December, 2007. As in the case of the amendments prepared for the Chinese Patent
Office and CIPO, the proposed amendments to the US patent expand the original claims to include a number of
therapeutic applications of the T36® formulation, including its use in cosmetics and in a microbicidal gel to prevent the
transmission of sexually transmitted infections (“STI’s”). On January 23, 2008 the USPTO issued a Filing Receipt for
the U.S. Continuation Patent Application (“the US CPA”) and assigned Serial No. 11/966,128 to the application. On
May 2, 2008, the USPTO issued an Office Action in relation to the US CPA. The matters raised in the Office Action
were addressed by the company and a Response was submitted to the USPTO in November, 2008. On January 5, 2009,
references cited in connection with a related patent application were submitted to the USPTO in an Information
Disclosure Statement (“IDS”) relating to the new U.S. application.The purpose of an IDS is to bring to the attention of
the Examiner any information that may pertain to the patentability of the claims of a patent application in order to
comply with the Duty of Disclosure imposed on patent Applicants under U.S. patent law. The onus is on the patent
Applicant to provide such information to the USPTO and the consequences can be serious if such information is not
provided to the USPTO. On January 16, 2009, the USPTO provided the Company with a Notice of Allowance for the
new U.S. patent application. However, it was determined that the U.S. Examiner had not considered the IDS filed
January 5, 2009, prior to issuing the Notice of Allowance. This was brought to the Examiner’s attention, who then
reviewed the IDS and provided a Supplemental Notice of Allowability on March 25, 2009. The Issue Fee and
Publication Fee were subsequently paid by the Company. As of the date of this report, the Company is awaiting further
correspondence from the USPTO in this regard. The Company still has a number of pending patent applications that
relate to the new U.S. application and should any new references or art be raised by a patent Examiner for any of these
applications prior to issuance of the application to patent, the Company will have to submit such art to the USPTO in
order to comply with the Duty of Disclosure, which in turn could result in the allowance of the application being
withdrawn. The issuance of the new U.S. application, therefore, while likely, is not guaranteed at this stage. Therefore,
at the time of this report, the Company has no assurance that any patent based on the US CPA will be granted at all and,
if any patent is granted, the Company cannot estimate when the patent will be granted or what claims will be allowed
and protected, if any.
Singapore
On February 18, 2005, the Singapore Patent Office accepted the PCT patent application and assigned it Patent
Application Number 200500987-3. On July 31, 2007, the Company was notified that the application had been
examined by the Intellectual Property Office of Singapore and satisfied the formal requirements of the Patent Act and
Rules of Singapore. Accordingly, the application was assigned Divisional Singapore Patent Application No.
200703677-5. The Company can now file a request for a combined Search and Examination Report by September 18,
2009.
Australia
On March 15, 2005 the PCT application was accepted for national examination by the Australian patent office on
March 15, 2005 and assigned with Patent Application Number 2002322916. On October 24, 2006, the Australian
patent office provided the Company with a Direction to Request Examination. Under Australian Patent law, such
examination must be requested within five years of the filing date or within six months of receiving a direction from
the Australian Patent Office, whichever is sooner. On October 10, 2007 the Company announced that the Australian
Patent Office had accepted the patent application with no objections. On December 4, 2007, a divisional application
was filed at the Australian Patent Office. As in the case of the amendments prepared for the Chinese Patent Office,
CIPO and the USPTO, the divisional application provides amendments to the Australian patent that expand the
original claims to include a number of therapeutic applications of the T36® formulation, including its use in cosmetics
and in a microbicidal gel to prevent the transmission of sexually transmitted infections (“STI’s”). A response from the
Australian Patent Office, concerning this application is still pending. On February 22, 2008, the Company announced
that Australian Patent Number 2002322916 has been issued by the Australia Patent Office. The patent provides
protection for the composition and production methods for ALDA’s T36® formulation until August 20, 2022. On
March 3, 2008, the Company was notified that the divisional application had been assigned Serial No. 2007237333
with an official filing date of August 20, 2002. Examination of the application was requested by the Company on June
3, 2008.
PCT application for anti-inflammatory, antiseptic therapeutic formulation
On March 20, 2008 the Company filed a comprehensive new patent application, International Application No.
PCT/CA2008/000536, “Antiseptic Compositions for the Treatment of Infections”, with CIPO under the Patent
Cooperation Treaty (PCT). The new PCT application seeks protection for the composition and preparation of T36®
formulations that also contain steroids, anesthetics or analgesics for use on topical infections and, in particular,
inflamed infections. Typically, infections with associated inflammation are treated with separate antiseptic and
anti-inflammatory preparations. The new T36® formulations combine these properties into a single treatment, making
the prescription process easier for the physician and the application easier for the patient.
In preliminary studies, under the direction of a physician, T36® formulations containing anti-inflammatory steroids
quickly resolved a number of skin infections, some of which had resisted all other treatments. Examples include
chronic eczema with secondary Staphylococcus infections and fungal infections, such as athlete’s foot, Tinea
versicolor.
On January 13, 2009, the Company was notified by its patent lawyers that an International Search Report (ISR) and
Written Opinion was issued by the International Searching Authority (ISA) on December 18, 2008. As part of the PCT
patent process, the ISA performs a search of prior art to identify any relevant art that may impact the patentability of a
PCT application. Generally, “prior art”consists of everything which has been made available to the public anywhere
in the world, for example, by means of a written disclosure (including drawings and other illustrations). The prior art is
“relevant” if it is capable of being of assistance in determining whether an invention, as claimed, is new and involves
an inventive step and was made available to the public before the international filing date. The ISA then issues a
preliminary and non-binding Written Opinion. This Written Opinion is an assessment by an Examiner on whether or
not a patent application conforms with respect to certain requirements for patentability. As disclosed above, references
cited in the Search Report and Written Opinion were submitted to the USPTO on January 5, 2009 in an Information
Disclosure Statement (“IDS”) relating to the new US CPA.
The claims made in this particular PCT application were purposefully very broad. Accordingly, the examiner for ISA
found a number of patents and other literature that, in the opinion of the examiner, represented prior art. At this time,
the Company does not need to take any action if National Examination of the PCT application is requested by January
20, 2010. As the National Examiners provide their responses to the PCT application, the Company can respond by
arguing against the opinions of the Examiners, or amending the claims.
As the time of writing, the Company has no assurance that any patents that have not yet been granted will be granted at
all and, if any patents are granted, the Company cannot estimate when the patents will be granted or what claims will
be allowed and protected, if any.
Rage Against The Machine
I like the fact that they are getting involved with Parkinson's, as my Brother In Law has advanced stage Parkinson's.
Rage Against The Machine
"Don't ever become a pessimist... a pessimist is correct oftener than an optimist, but an optimist has more fun, and neither can stop the march of events. Robert A. Heinlein"
Apparently, I answered my own question; and I promise that I will download the program and resize it.
Rage Against the Machine
Ok, how do you make the avatar show up at the bottom of the post? Apparently, I will have to resize it as well.
Thank You
Newbie
Rage Against The Machine
Good post geezy! Just got into this stock a few weeks ago because of a recommendation from a longer time member on these boards; now I wait for it to unfold and possibly make me a nice chunk of change. Today is Friday and the only things I will be doing is buying more if it drops again, and then go camping for the weekend. Have a good day all!
Rage Against The Machine
"Don't ever become a pessimist... a pessimist is correct oftener than an optimist, but an optimist has more fun, and neither can stop the march of events. Robert A. Heinlein"
Stem Cell Therapeutics Announces Issuance of Additional US Patent for Use of Prolactin
3 hours ago - ACQUIREMEDIA
CALGARY, ALBERTA--(Marketwire - May 19, 2009) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) has been issued United States Patent No. 7,534,765, entitled "Pregnancy Induced Oligodendrocyte Precursor Cell Proliferation Regulated by Prolactin". This patent, issued today, covers methods of using of prolactin for enhancing the formation of oligodendendrocytes in vivo, such as to treat diseases associated with loss of myelin-producing oligodendrocytes (white matter diseases).
Dr. Alan Moore, President and CEO, commented as follows:
"This patent bolsters our intellectual property position around the use of prolactin for treating demyelinating neurodegenerative diseases such as multiple sclerosis ("MS") in which the myelin sheath surrounding the axon of neurons is damaged. The finding that prolactin enhances oligodendrocyte production and remyelination is what stimulated the development of our NTx(R)-488 program for MS, with preclinical studies being completed in preparation for Phase II clinical trials.
Importantly, as covered by other SCT patents, prolactin also stimulates neural stem cell proliferation and neurogenesis. Prolactin is therefore expected to repair both the myelin damage and the neuronal damage in MS, which is necessary for full functional recovery, and makes prolactin a unique MS drug candidate."
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis Huntington's disease, Alzheimer's disease, and ALS.
These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.
Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT:
Stem Cell Therapeutics Corp.
Alan Moore, PhD
President and CEO
(403) 245-5495 ext.224
Email: amoore@stemcellthera.com
Stem Cell Therapeutics Corp.
Chloe Douglas-Crampton
Investor Relations
(403) 245-5495 ext. 221
Email: crampton@stemcellthera.com
Website: www.stemcellthera.com
Source: Stem Cell Therapeutics Corp.
Rage Against The Machine
ALDA Products Popular at O.D.A. Meeting in Toronto
VANCOUVER, BRITISH COLUMBIA, May 5, 2009 (Marketwire via COMTEX News Network) --
Representatives of ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) ("the Company" or "ALDA") attended the 142nd Annual Spring Meeting ("ASM") of the Ontario Dental Association ("ODA") on April 30 and May 1, 2009. This meeting is the largest dental conference held in Canada and took place at the Metro Toronto Convention Centre. Joining over 275 other exhibitors at the ASM, ALDA presented its new product line to over 10,000 dentists and 25,000 dental staff.
The products on display included:
- T36(R) Disinfectant
- T36(R) Disinfectant Wipes
- T36(R) Antiseptic Hand Sanitizer Gel
- T36(R) Antiseptic Hand Sanitizer Wipes
- T36(R) Disinfectant Cleaner CONCENTRATE
All of the products attracted significant interest and a large number of samples were provided to the attendees. The safety and efficacy of T36(R) Disinfectant was of particular interest as was the ability of T36(R) Antiseptic Hand Sanitizer to kill Norwalk-like viruses and to have a residual anti-microbial effect, unlike typical alcohol-based hand sanitizers. As a result, T36(R) Antiseptic Hand Sanitizer Gel and canisters holding 160 T36(R) Antiseptic Hand Sanitizer Wipes were very popular. With the addition of T36(R) Disinfectant Cleaner CONCENTRATE to the product line, the attendees recognized that ALDA's products can satisfy all of their infection control needs.
Dr. Terrance Owen, President & CEO, states, "It was very gratifying to see such a positive response to our products. Certainly this was enhanced by the concern over H1N1, the so-called "swine flu". People were very surprised when, as a demonstration of the safety of our products, we sprayed T36(R) Disinfectant directly onto our hands. Everyone who tried T36(R) Antiseptic Hand Sanitizer told us that they think it is superior to other comparable products and, when they learned about the greater efficacy and residual effect, were even more interested. We will now be working towards capitalizing on the enthusiasm generated from this conference and commencing our marketing program as soon as possible."
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.
Terrance G. Owen, Ph.D., MBA, President & CEO
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
SOURCE: ALDA Pharmaceuticals Corp.
ALDA Pharmaceuticals Corp.Peter ChenDistribution & Sales Contact(604) 521-8300 Ext. 3(604) 521-8322 (FAX)peter_chen@aldacorp.comALDA Pharmaceuticals Corp.Scott YoungInvestor Relations Contact(604) 288-7222syoung@freeformcom.comwww.aldacorp.com
Copyright (C) 2009 Marketwire. All rights reserved.
Rage Against The Machine
ALDA PHARMACEUTICALS Halted!
Rage Against The Machine
ALDA Receives Delivery of New T36(R) Antiseptic Hand Sanitizer
VANCOUVER, BRITISH COLUMBIA, Dec 10, 2008 (Marketwire via COMTEX News Network) --
ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("the Company" or "ALDA") announces that its T36(R) Antiseptic Hand Sanitizer Gel (DIN 02314320), the first ALDA product that has been approved for human use by Health Canada, has been manufactured and delivered, and is now ready to be shipped to distributors.
Compared to typical alcohol-based hand sanitizers, ALDA's T36(R) Antiseptic Hand Sanitizer is a unique formula with two active ingredients that provide faster action against a broader range of infectious organisms and offer a long-lasting residual effect.
Group 270 Sales & Marketing Inc. ("Group 270"), ALDA's marketing agent, will be introducing T36(R) Antiseptic Hand Sanitizer to major regional and national pharmacy chains across Canada. The Company's current distributors will also be providing this new product to their customers. Other marketing activities are being initiated that are designed to penetrate additional market sectors not currently serviced by the Company.
About ALDA Pharmaceuticals
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
SOURCE: ALDA Pharmaceuticals Corp.
ALDA Pharmaceuticals Corp. Peter Chen Distribution & Sales Contact (604) 521- 8300 Ext. 3 (604) 521-8322 (FAX) Email: peter_chen@aldacorp.com ALDA Pharmaceuticals Corp. Scott Young Investor Relations Contact (604) 288-7222 Email: syoung@freeformcom.com Website: www.aldacorp.com
Copyright (C) 2008 Marketwire. All rights reserved.
Rage Against The Machine
You delete my post; but you allow drumstick to post his whining drivel. Good site you have here. See you janetcanada, it was a pleasure.
Rage Against The Machine
I won’t lie. Drumstick, I have to say, I never thought I would put anyone on ignore on this particular site; but you’re gone (Not that it matters to you or anyone else). I felt sorry for you once; but you are a whining idiot. Go to Stockhouse or Agoracom. I’m pretty sure your agenda will be accepted with open arms there by most.
All I can say is that your comments are not constructive to this investment of mine. If I was trying to capitalize on what I thought was a good thing, I’m pretty sure I wouldn’t be criticizing every +/- move the company has made.
I could be wrong, but I think you are working for minimum wage in the stock market and have never traded a share in your life, as you would not know where to begin.
Rage Against The Machine